Stants Kristen
SEC CIK 1805727 · EDGAR
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| DNTH | Dianthus Therapeutics, Inc. /DE/ | CHRO | 20.3K | — | $38.6K | 4 | 2021-09-14 | 2022-11-30 |
Most active insiders at DNTH, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Garcia Marino | CEO AND Pres, Dir | — | $27.96M |
| 2 | Randhawa Simrat | EVP, Head of R, D | — | $15.00M |
| 3 | Savitz Ryan | EVP, CFO, CBO | — | $14.29M |
| 4 | CARR EDWARD | CAO | — | $5.59M |
| 5 | Veness Adam M | SVP, GC, Sec | — | $4.63M |
| 6 | Soteropoulos Paula | Dir | — | $2.25M |
| 7 | McGeorge Anne | Dir | — | $844.8K |
| 8 | Read Simon | Dir | — | $630.8K |
Stants Kristen made no open-market trades at DNTH in the last 12 months.
Transactions 4
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-12-02 | 2022-11-30 | DNTH | Dianthus Therapeutics, Inc. /DE/ | Stants Kristen | CHRO | A - Grant | $0.94 | +3,000 | 20.3K | +17% | +$2,820 | |
| 2022-06-06 | 2022-05-31 | DNTH | Dianthus Therapeutics, Inc. /DE/ | Stants Kristen | CHRO | A - Grant | $0.99 | +3,000 | 17.3K | +21% | +$2,970 | |
| 2021-09-20 | 2021-09-16 | DNTH | Dianthus Therapeutics, Inc. /DE/ | Stants Kristen | CHRO | S - Sale | $6.73 | -5,736 | 14.3K | -29% | -$38.6K | |
| 2021-09-16 | 2021-09-14 | DNTH | Dianthus Therapeutics, Inc. /DE/ | Stants Kristen | CHRO | A - Grant | $0.00 | +20.0K | 20.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations